DiaMedica Therapeutics (DMAC) FY 2025 Conference May 20, 2025 03:30 PM ET Speaker0 Matthew Caulfield. I'm a senior biotech analyst here at H. C. Wainwright. Our next company is DiaMedica Therapeutics. I'm joined by David Wenbecki, chief business officer. So thank you to DiaMedica for being here. Thanks for having us, Matt. We really appreciate it. Absolutely. So maybe to start things off at a high level, DMedica has a platform focused on ischemic diseases with biologic asset DM199. Can you talk to us about ...